Achilles Therapeutics (NASDAQ:ACHL) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Achilles Therapeutics (NASDAQ:ACHLGet Rating) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage currently has $2.25 target price on the stock.

According to Zacks, “Achilles Therapeutics plc is a clinical-stage biopharmaceutical company. It engages in developing precision T cell therapies to treat solid tumors. Achilles Therapeutics plc is based in LONDON. “

Separately, Piper Sandler reduced their price target on Achilles Therapeutics from $20.00 to $17.00 in a research report on Tuesday.

ACHL opened at $2.01 on Wednesday. The stock’s 50-day moving average price is $2.71 and its 200 day moving average price is $3.97. Achilles Therapeutics has a 12-month low of $1.84 and a 12-month high of $14.49. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.03. The firm has a market cap of $81.61 million, a price-to-earnings ratio of -0.21 and a beta of 0.25.

Achilles Therapeutics (NASDAQ:ACHLGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. On average, research analysts forecast that Achilles Therapeutics will post -2.03 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in ACHL. Goldman Sachs Group Inc. purchased a new position in Achilles Therapeutics during the 4th quarter worth approximately $65,000. Legal & General Group Plc purchased a new position in Achilles Therapeutics during the 4th quarter worth approximately $124,000. Renaissance Technologies LLC purchased a new position in Achilles Therapeutics during the 4th quarter worth approximately $128,000. Geode Capital Management LLC purchased a new position in Achilles Therapeutics during the 3rd quarter worth approximately $137,000. Finally, Sender Co & Partners Inc. purchased a new position in Achilles Therapeutics during the 4th quarter worth approximately $139,000. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Achilles Therapeutics Company Profile (Get Rating)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

Featured Articles

Get a free copy of the Zacks research report on Achilles Therapeutics (ACHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.